- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06090162
LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (SAKK 38/23)
LIBERTY: Liquid Biopsy to Diagnose and Monitor Central Nervous System (CNS) Involvement in High-risk B Cell Non-Hodgkin Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Non-Hodgkin B-cell lymphoma (B-NHL) are cancers that arise from a subtype of white blood cells (lymphocyte) and typically involve the lymphatic system; they represent 4% of all cancers [SEER database, access 2022]. Despite booming novel antineoplastic agent development, a significant number of aggressive B-NHL patients continue to succumb to their disease, experiencing rapidly progressive disease or early relapse. Central nervous system or CNS (brain, spinal cord and cerebrospinal fluid (CSF)) involvement in aggressive B-NHL is a rare (2-5%) but it is a devastating event, with a life expectancy ranging between 2 and 5 months [PMID: 30125215]. Circulating tumor DNA (ctDNA) represents fragmented DNA that originates from tumors cells, carrying specific cancer-associated mutations that can be detected in the blood or other fluids subsumed under "liquid biopsies".
The role of ctDNA gained momentum with the advent of high throughput sequencing technologies, becoming increasingly relevant for clinical practice. In lymphoma, detecting and monitoring ctDNA has been shown to be feasible and of high prognostic relevance regarding response and relapse. As such, ctDNA is emerging as a promising biomarker that can provide valuable diagnostic and prognostic information [PMID: 30125215, PMID: 29449275]. Identification of patients suffering from aggressive B-NHL at high risk of CNS relapse remains extremely challenging and currently mainly relies on a clinical score (CNS-IPI) [PMID: 27382100]. The detection of asymptomatic CNS is limited to conventional techniques and is not standardized [PMID: 22927246]. In patients with biopsy-proven CNS lymphoma, ctDNA can be detected in CSF (CSF ctDNA) in approximately 95% of cases. Furthermore, CSF ctDNA is predictive of CNS relapse in a small series of neurologically asymptomatic patients with aggressive B-NHL [PMID: 36542815, PMID: 32079701, PMID: 34551072]. Prevention and treatment of CNS involvement remains a great unmet clinical need. The discovery of novel and robust biomarkers is of paramount importance for early detection and risk-adapted therapeutic strategies for CNS involvement. The investigators hypothesize that CSF ctDNA is superior to current standard diagnostic procedures (e.g., flowcytometry or cytology) to detect CNS involvement in high-risk patients.
Furthermore, in patients with positive CSF ctDNA, the investigators also postulate that the concept of monitoring minimal residual disease (MRD, small amount of ctDNA that persists in patients that have no signs of active disease on standard imaging techniques) will provide additional information on patient prognosis.
This is a multicenter prospective diagnostic study to compare the performance of experimental diagnostic test (ctDNA) versus conventional cytology (CC) and flow cytometry (FC). Each high-risk B-NHL participant will proceed through standard work-up to evaluate potential CNS involvement including a neurological physical examination, a brain MRI and a diagnostic lumbar puncture. Each participant's CSF will be assessed by the two diagnostic tests (CSF ctDNA and conventional test (CC/FC)); the gold standard being proven CNS lymphoma involvement.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Noémie Lang, MD
- Phone Number: +41 022 372 33 11
- Email: noemie.lang@hcuge.ch
Study Contact Backup
- Name: Sabrina Chiquet
- Phone Number: +41 31 389 91 91
- Email: trials@sakk.ch
Study Locations
-
-
-
Aarau, Switzerland, 5001
- Not yet recruiting
- Kantonspital Aarau
-
Contact:
- Marc Heizmann, MD
- Phone Number: +41 62 838 60 50
- Email: marc.heizmann@ksa.ch
-
Principal Investigator:
- Marc Heizmann, MD
-
Basel, Switzerland, 4056
- Recruiting
- Universitätsspital Basel
-
Contact:
- Benjamin Kasenda, MD
- Phone Number: +41 61 265 50 74
- Email: benjamin.kasenda@usb.ch
-
Principal Investigator:
- Benjamin Kasenda, MD
-
Bellinzona, Switzerland, 6500
- Not yet recruiting
- Istituto Oncologico della Svizzera Italiana (IOSI)
-
Contact:
- Maria Pirosa, MD
- Phone Number: +41 91 811 94 79
- Email: maria.pirosa@eoc.ch
-
Principal Investigator:
- Maria Pirosa, MD
-
Bern, Switzerland, 3010
- Recruiting
- Inselspital Bern - Universitätsklinik für Medizinische Onkologie
-
Principal Investigator:
- Urban Novak, MD
-
Contact:
- Urban Novak, MD
- Phone Number: +41 31 632 22 43
- Email: urban.novak@insel.ch
-
Chur, Switzerland, 7000
- Recruiting
- Kantonsspital Graubunden
-
Principal Investigator:
- Ulrich Mey, Prof
-
Contact:
- Ulrich Mey, Prof
- Phone Number: 41 81 256 71 70
- Email: ulrich.mey@ksgr.ch
-
Fribourg, Switzerland, 1708
- Recruiting
- Hôpital Fribourgeois - Hôpital Cantonal
-
Principal Investigator:
- Gaëlle Rhyner Agocs, MD
-
Contact:
- Gaëlle Rhyner Agocs, MD
- Phone Number: +41 26 306 00 00
- Email: gaelle.rhyner@h-fr.ch
-
Geneva, Switzerland, 1205
- Recruiting
- Hopitaux Universitaire de Genève (HUG)
-
Principal Investigator:
- Noémie Lang, MD
-
Contact:
- Noémie Lang, MD
- Phone Number: +41 22 372 33 11
- Email: noemie.lang@hcuge.ch
-
Lausanne, Switzerland, 1011
- Not yet recruiting
- CHUV - Départment d'oncologie
-
Contact:
- Amandine Segot, MD
- Phone Number: +41 78 212 58 64
- Email: amandine.segot@chuv.ch
-
Principal Investigator:
- Amandine Segot, MD
-
Liestal, Switzerland, 4410
- Recruiting
- Kantonsspital Baselland
-
Contact:
- Michèle Voegeli, MD
- Phone Number: +41 61 925 27 10
- Email: michele.voegeli@ksbl.ch
-
Principal Investigator:
- Michèle Voegeli, MD
-
Sion, Switzerland, 1951
- Recruiting
- Hôpital du Valais, Hôpital de Sion
-
Contact:
- Grégoire Berthod, MD
- Phone Number: +41 27 603 87 71
- Email: gregoire.berthod@hopitalvs.ch
-
Principal Investigator:
- Grégoire Berthod, MD
-
St. Gallen, Switzerland, 9007
- Recruiting
- Kantonsspital St. Gallen
-
Principal Investigator:
- Felicitas Hitz, MD
-
Contact:
- Felicitas Hitz, MD
- Phone Number: +41 71 494 11 11
- Email: felicitas.hitz@kssg.ch
-
Zurich, Switzerland, 8032
- Recruiting
- Klinik für Hämatologie und Onkologie Hirslanden Zürich
-
Contact:
- Christoph Renner, Prof
- Phone Number: +41 43 387 37 80
- Email: christoph.renner@kho.ch
-
Principal Investigator:
- Christoph Renner, Prof
-
Zürich, Switzerland, 8063
- Recruiting
- Stadtspital Triemli Zürich
-
Principal Investigator:
- Adrian Schmidt, MD
-
Contact:
- Adrian Schmidt, MD
- Phone Number: +41 44 416 35 05
- Email: adrian.schmidt@stadtspital.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Informed consent as documented by signature before registration and prior to any trial specific procedures, according to Swiss law and ICH E6 regulations Swiss law and ICH GCP E6(R2) regulations before registration.
- Histologically and/or cytologically confirmed newly diagnosed lymphomas including the following:
Diffuse large B-cell lymphoma (DLBCL) with at least one of the following characteristics:
- CNS IPI > 4
- Non-GC/ABC subtype with IPI > 3
- Testicular involvement
- Breast involvement
- Kidney involvement
- Adrenal involvement
- Paranasal sinus / orbit involvement
- Involvement of ≥ 3 extranodal sites
- HIV-positive
- Radiological or histological CNS involvement
- High-grade B-cell lymphoma with MYC translocation with BCL2 and / or BCL6 (HGBL)
- Burkitt lymphoma
- Mantle cell lymphoma (blastoid variant or Ki67 >30% or TP53 mutated)
- Primary CNS lymphoma
Note:
- Aggressive transformation from indolent lymphomas (pretreated or not) are allowed
Patients enrolled in other clinical trials may be included
- Patients must be willing to undergo a lumbar puncture at screening
- Age ≥ 18 years
Exclusion Criteria:
- Subtypes of Non-Hodgkin lymphoma (NHL) not fulfilling above mentioned criteria (e.g., indolent lymphoma, T-cell lymphoma)
- Relapsing B-NHL
- Low/intermediate-risk DLBCL (CNS-IPI < 4) AND no CNS involvement on imaging
- Any prior lymphoma-directed therapy before registration, with the exception of a maximum of 48 hours steroids prior to lumbar puncture procedure and therapies received for indolent lymphomas prior to transformation
- Any active advanced or metastatic cancer
- Any clinical contraindication to lumbar puncture procedure as per local guidelines
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned diagnostic procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: experimental diagnostic test
Lumbar punction at diagnosis.
CSF and blood samples will be assessed by the two diagnostic tests (CSF ctDNA and conventional test (CC/FC))
|
ctDNA detection on CSF and blood
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity
Time Frame: at baseline
|
Sensitivity of liquid biopsy (ctDNA) measured within CSF in its performance to detect CNS involvement in newly diagnosed high-risk B-NHL in comparison to standard conventional diagnostic approaches (CC / FC). For the evaluation of the primary endpoint, only patients with confirmed CNS involvement at baseline (real positives) will be analyzed. CNS involvement at baseline is defined as having at least one of the following conditions:
|
at baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specificity
Time Frame: at baseline
|
Specificity of liquid biopsy (ctDNA) measured within CSF in its performance to detect CNS involvement in newly diagnosed high-risk B-NHL in comparison to standard conventional diagnostic approaches (CC / FC). For the evaluation of specificity, only patients without CNS involvement at baseline (real negatives) will be analyzed. Absence of CNS involvement at baseline is defined as having none of the following conditions:
|
at baseline
|
Time to lymphoma manifestation in the CNS
Time Frame: from the date of registration until the date of assessment of neurological symptoms or death due to lymphoma, assessed up to 1 year after registration
|
Time to lymphoma manifestation in the CNS, defined as time from diagnosis to one of the following events, whatever occurs first:
|
from the date of registration until the date of assessment of neurological symptoms or death due to lymphoma, assessed up to 1 year after registration
|
Progression-free survival (PFS)
Time Frame: from the date of registration until the date of progression or relapse as per Lugano and / or IPCG criteria, or death whatever occurs first, assessed up to 1 year after registration
|
PFS is defined as the time from diagnosis to lymphoma progression or relapse as per Lugano and / or IPCG criteria, or death whatever occurs first.
Patients not having an event at the time of the analysis will be censored at the date of their last tumor assessment showing non-progression.
|
from the date of registration until the date of progression or relapse as per Lugano and / or IPCG criteria, or death whatever occurs first, assessed up to 1 year after registration
|
Event-free survival (EFS)
Time Frame: from the date of registration until the date of progression or relapse as per Lugano and / or IPCG criteria, treatment stop without achieving a complete response or death whatever occurs first, assessed up to 1 year after registration
|
EFS is defined as the time from diagnosis to lymphoma progression or relapse as per Lugano and / or IPCG criteria, treatment stop without achieving a complete response or death whatever occurs first.
Patients not having an event at the time of analysis will be censored at the date of their last tumor assessment showing non-progression.
This endpoint will be calculated separately for each treatment line.
|
from the date of registration until the date of progression or relapse as per Lugano and / or IPCG criteria, treatment stop without achieving a complete response or death whatever occurs first, assessed up to 1 year after registration
|
Overall survival (OS)
Time Frame: from the date of registration until the date of death, assessed up to 1 year after registration
|
OS will be calculated from diagnosis until death from any cause.
Patients not experiencing an event will be censored at the last date they were known to be alive.
|
from the date of registration until the date of death, assessed up to 1 year after registration
|
Overall response rate (ORR)
Time Frame: At the date of tumor assessment according to the Lugano criteria, assessed up to 1 year after registration
|
Overall response rate (ORR) is defined as either PR or CR according to the Lugano criteria. Patients with no tumor assessment will be considered:
|
At the date of tumor assessment according to the Lugano criteria, assessed up to 1 year after registration
|
Duration of response (DOR)
Time Frame: from the date of first response CR until the date of lymphoma progression, relapse or death, whatever occurs first, assessed up to 1 years after registration
|
DOR is evaluated in all patients who achieved a CR after the end of the intended treatment.
DOR is defined as time from first complete response until lymphoma progression, relapse or death, whatever occurs first.
Response and progression are evaluated according to Lugano criteria.
Patients not having an event at the time of analysis will be censored at the date of their last tumor assessment showing non-progression.
|
from the date of first response CR until the date of lymphoma progression, relapse or death, whatever occurs first, assessed up to 1 years after registration
|
Time to minimal residual disease (MRD) negativity
Time Frame: from the date of first documented MRD positivity (CSF ctDNA detected positive) to the date of first documented MRD negativity, assessed up to 1 years after registration
|
Time from first documented MRD positivity (CSF ctDNA detected positive) to first documented MRD negativity.
Patients not reaching MRD negativity will be censored at the last time they were known to be MRD positive.
Evaluated only in patients with documented MRD positivity at any time.
|
from the date of first documented MRD positivity (CSF ctDNA detected positive) to the date of first documented MRD negativity, assessed up to 1 years after registration
|
Collaborators and Investigators
Investigators
- Study Chair: Noémie Lang, MD, Hôpitaux Universitaires Genève
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAKK 38/23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-hodgkin Lymphoma, B Cell
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Taiwan, Australia
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
Clinical Trials on ctDNA detection
-
Shanghai Zhongshan HospitalFudan University; Amoy Diagnostics Co., LTDNot yet recruitingPatients With Non-metastatic Pancreatic Cancer | Evaluation of Tumor Resectability Shall be Made in Consensus at Multidisciplinary Meetings, According to NCCN Guideline Version 1.2022 Pancreatic AdenocarcinomaChina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen UniversityUnknownNon-small Cell Lung Cancer Stage IChina
-
Second Xiangya Hospital of Central South UniversityShanghai OrigiMed Co., Ltd.RecruitingLung Squamous Cell CarcinomaChina
-
BAIYONG SHENGeneCast Biotechnology Co., Ltd.Not yet recruitingPancreatic Cancer ResectableChina
-
Second Xiangya Hospital of Central South UniversityGeneplus-Beijing Co. Ltd.Not yet recruitingNon-small Cell Lung CancerChina
-
Fang WuZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Sun Yat-sen... and other collaboratorsRecruitingAdvanced Lung Non-Small Cell CarcinomaChina
-
Peking UniversityRecruitingHER2 Positive Advanced Gastric CancerChina
-
First People's Hospital of HangzhouCompletedNon-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer MetastaticChina
-
Shanghai Chest HospitalUnknown
-
Peking University Cancer Hospital & InstituteRecruitingColon Cancer | Circulating Tumor DNAChina